Ocugen (OCGN) Scheduled to Post Quarterly Earnings on Thursday

Ocugen (NASDAQ:OCGN) will issue its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm had revenue of $1.01 million during the quarter. During the same period last year, the firm posted ($0.07) earnings per share. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Trading Up 6.6 %

Shares of OCGN stock opened at $1.30 on Wednesday. The company has a market capitalization of $333.27 million, a PE ratio of -5.18 and a beta of 3.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.87 and a current ratio of 1.87. The business’s fifty day moving average is $1.58 and its 200 day moving average is $1.34. Ocugen has a 52-week low of $0.35 and a 52-week high of $2.11.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Wednesday, May 15th. Chardan Capital reiterated a “buy” rating and set a $5.00 price objective on shares of Ocugen in a research report on Wednesday, May 15th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.